Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “overweight” rating reissued by analysts at J P Morgan Chase & Co in a research report issued to clients and investors on Wednesday.

FOLD has been the topic of a number of other research reports. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 19th. BidaskClub lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 11th. Chardan Capital reissued a “buy” rating and issued a $16.50 price objective (down from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Robert W. Baird upped their price objective on shares of Amicus Therapeutics from $12.00 to $15.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 12th. Finally, Cowen and Company restated an “outperform” rating and issued a $18.00 target price (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, September 14th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Amicus Therapeutics presently has a consensus rating of “Buy” and an average price target of $17.58.

Amicus Therapeutics (NASDAQ:FOLD) traded up 9.21% during trading on Wednesday, hitting $16.24. 10,581,939 shares of the company traded hands. The company’s 50-day moving average is $13.82 and its 200 day moving average is $10.45. The firm’s market cap is $2.67 billion. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $16.60.

Amicus Therapeutics (NASDAQ:FOLD) last posted its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The firm had revenue of $7.16 million during the quarter, compared to the consensus estimate of $6.96 million. During the same period in the prior year, the business earned ($0.40) EPS. On average, equities analysts anticipate that Amicus Therapeutics will post ($1.31) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was first published by Marea Informative and is the property of of Marea Informative. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at http://www.mareainformativa.com/amicus-therapeutics-fold-overweight-rating-reaffirmed-at-j-p-morgan-chase-co/116046/.

In related news, major shareholder Life Sciences Maste Perceptive purchased 1,500,000 shares of Amicus Therapeutics stock in a transaction dated Thursday, July 13th. The stock was bought at an average cost of $12.25 per share, for a total transaction of $18,375,000.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 3.40% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Teacher Retirement System of Texas raised its holdings in shares of Amicus Therapeutics by 1.7% in the second quarter. Teacher Retirement System of Texas now owns 10,243 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 169 shares during the last quarter. DORCHESTER WEALTH MANAGEMENT Co acquired a new stake in shares of Amicus Therapeutics during the second quarter valued at $111,000. Tudor Investment Corp ET AL acquired a new stake in shares of Amicus Therapeutics during the second quarter valued at $124,000. Aperio Group LLC boosted its stake in shares of Amicus Therapeutics by 13.5% during the second quarter. Aperio Group LLC now owns 13,986 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 1,663 shares during the last quarter. Finally, Zacks Investment Management acquired a new stake in shares of Amicus Therapeutics during the second quarter valued at $145,000.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Stock Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related stocks with our FREE daily email newsletter.